Barbara Leyman
Director/Board Member at Complix NV
Network origin in Barbara Leyman first degree
Entity | Entity type | Industry | |
---|---|---|---|
Limburgse Reconversie Maatschappij NV
Limburgse Reconversie Maatschappij NV Investment ManagersFinance Limburgse Reconversie Maatschappij NV (LRM) is an independent private equity firm which was founded in 1994 by the Flemish government. Limburgse Reconversie Maatschappij NV is headquartered in Hasselt, Beglium.
14
| Private Company | Investment Managers | 14 |
Amakem NV
Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium.
7
| Private Company | Medical/Nursing Services | 7 |
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Barbara Leyman via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Katholieke Universiteit Leuven | College/University | Graduate Degree Graduate Degree Corporate Officer/Principal Graduate Degree | |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
ABLYNX | Biotechnology | Director/Board Member Chief Executive Officer | |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Founder | |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | Director/Board Member Corporate Officer/Principal | |
OXURION NV | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
FlandersBio vzw
FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Director/Board Member Founder | |
KeyGene NV
KeyGene NV Miscellaneous Commercial ServicesCommercial Services KeyGene NV provides its partners and customers in the plant breeding industry contract research, partnerships and molecular genetic services. It delivers novel enabling technologies and applications to support companies and institutes that carry out fundamental or applied genetic genomic research and that seek to enhance the quality of their products through the improvement of their genetic material. The company was established in 1989 and is headquartered in Wageningen, the Netherlands. | Miscellaneous Commercial Services | President Corporate Officer/Principal | |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member Chairman | |
Université Libre de Bruxelles | College/University | Doctorate Degree Corporate Officer/Principal | |
University of Utrecht | College/University | Doctorate Degree Doctorate Degree | |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman | |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Pharmaceuticals: Major | Sales & Marketing | |
Complement Therapeutics Ltd.
Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Pharmaceuticals: Major | Director/Board Member | |
SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member | |
Top Institute Pharma
Top Institute Pharma BiotechnologyHealth Technology Part of Center for Translational Molecular Medicine, Top Institute Pharma provides pharmaceutical research services. The company is based in Leiden, Netherlands. Top Institute Pharma was acquired by Center for Translational Molecular Medicine on June 09, 2015. | Biotechnology | Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member | |
WILSON THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member | |
HANSA BIOPHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
Top Sector Life Sciences & Health | Director/Board Member | ||
Nefarma | Director/Board Member | ||
VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chairman | |
NeRRe Therapeutics Holdings Ltd.
NeRRe Therapeutics Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services NeRRe Therapeutics Holdings Ltd. is a British biotechnology company founded in 2017. The private company is based in Stevenage, UK. The company is engaged in research and development of biotechnology. | Miscellaneous Commercial Services | Director/Board Member | |
INIM Pharma AB
INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
PHARVARIS N.V. | Pharmaceuticals: Major | Founder | |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Founder | |
Organon International BV | President | ||
Fondation Ophtalmologique Adolphe de Rothschild
Fondation Ophtalmologique Adolphe de Rothschild Hospital/Nursing ManagementHealth Services Fondation Ophtalmologique Adolphe de Rothschild is a specialized hospital in Paris, FR that focuses on treating all pathologies related to the head and neck for both adults and children. The hospital has a pharmacy that ensures the supply of medicines and medical devices. The hospital also has a clinical research service that serves as a one-stop-shop for investigators and industrial or academic partners. The hospital is supported by the Edmond de Rothschild Foundations, which offer a Medical Fellowship program to support talented and promising young practitioners in their hospital-university dynamic. The CEO of the French company is Julien Gottsmann. | Hospital/Nursing Management | Director/Board Member | |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor | |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Director/Board Member | |
Stanford Graduate School of Business | College/University | Graduate Degree | |
Rhone-Poulenc Group | Public Communications Contact | ||
United Nations High Commissioner for Refugees
United Nations High Commissioner for Refugees Services to the Health IndustryHealth Services The United Nations High Commissioner for Refugees, also known as UNHCR, is an organization that is committed to protecting the rights of refugees, forcibly displaced communities, and stateless individuals. The non-profit company is based in Suisse, Switzerland. The Swiss company's mission is to save lives and provide assistance to those who have been forced to flee their homes due to conflict, persecution, or other forms of violence. | Services to the Health Industry | Corporate Officer/Principal | |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | Medical/Nursing Services | Director/Board Member | |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
GENKYOTEX SA. | Pharmaceuticals: Major | Director/Board Member | |
Sciences Po | College/University | Undergraduate Degree | |
Université Catholique de Louvain | College/University | Corporate Officer/Principal | |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
Netherlands | 11 |
Belgium | 10 |
Switzerland | 10 |
United States | 8 |
France | 8 |
Sectoral
Health Technology | 31 |
Consumer Services | 7 |
Commercial Services | 7 |
Health Services | 4 |
Finance | 2 |
Operational
Director/Board Member | 144 |
Corporate Officer/Principal | 39 |
Private Equity Investor | 22 |
Chief Tech/Sci/R&D Officer | 13 |
Doctorate Degree | 12 |
Most connected contacts
Insiders | |
---|---|
Bruno Montanari | 30 |
Patrick van Beneden | 28 |
Johannes G. C. P. Schikan | 22 |
Gilles Nobécourt | 19 |
Geert-Jan Mulder | 17 |
Lieven de Jonge | 15 |
George Lasezkay | 14 |
Hilde Essers | 13 |
Gaston Matthyssens | 12 |
Mark Vaeck | 10 |
Debora Dumont | 10 |
Kieran Rooney | 9 |
Ignace Lasters | 9 |
Michael Palfreyman | 9 |
Stephen Pakola | 8 |
- Stock Market
- Insiders
- Barbara Leyman
- Company connections